Literature DB >> 11720770

Studies on the antinociceptive effect of [Nphe1]nociceptin(1-13)NH2 in mice.

A Di Giannuario1, A Rizzi, S Pieretti, R Guerrini, R Bertorelli, S Salvadori, D Regoli, G Calo.   

Abstract

Nociceptin/orphanin FQ (NC) and its receptor (OP(4)) have been implicated in the regulation of various functions including nociception. [Nphe(1)]NC(1-13)NH(2) (Nphe) is a selective OP(4) antagonist which prevents the pronociceptive effects of supraspinal NC and causes per se a naloxone-insensitive antinociceptive effect. In the present study, we tested Nphe in wild type (WT) and OP(4) receptor knock out mice and found that a clear antinociceptive effect of the antagonist was evident only in WT mice. Moreover, we evaluated, over 5 days of treatment, the antinociceptive effects of Nphe in comparison with those of DAMGO and found that tolerance develops to the effects of the opioid receptor agonist but not to Nphe. These data demonstrate that the antinociceptive action of Nphe is due to the block of OP(4) receptors and that no tolerance develops to this kind of antinociception.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720770     DOI: 10.1016/s0304-3940(01)02352-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

1.  [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.

Authors:  Girolamo Calo; Anna Rizzi; Daniela Rizzi; Raffaella Bigoni; Remo Guerrini; Giuliano Marzola; Matteo Marti; John McDonald; Michele Morari; David G Lambert; Severo Salvadori; Domenico Regoli
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

2.  In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Authors:  Federica Ferrari; Maria Camilla Cerlesi; Davide Malfacini; Laila Asth; Elaine C Gavioli; Blair V Journigan; Uma Gayathri Kamakolanu; Michael E Meyer; Dennis Yasuda; Willma E Polgar; Anna Rizzi; Remo Guerrini; Chiara Ruzza; Nurulain T Zaveri; Girolamo Calo
Journal:  Eur J Pharmacol       Date:  2016-10-22       Impact factor: 4.432

3.  The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.

Authors:  Ling Jong; Nurulain Zaveri; Lawrence Toll
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

Review 4.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

Review 5.  Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.

Authors:  Nurulain Zaveri
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

6.  Activities of mixed NOP and mu-opioid receptor ligands.

Authors:  B Spagnolo; G Calo; W E Polgar; F Jiang; C M Olsen; I Berzetei-Gurske; T V Khroyan; S M Husbands; J W Lewis; L Toll; N T Zaveri
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.